FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2116696460> ?p ?o ?g. }

• W2116696460 endingPage "805" @default.
• W2116696460 startingPage "805" @default.
• W2116696460 abstract "Study Objective: To evaluate the toxicity and clinical efficacy of interferon-α2b (IFN-α) in patients with asymptomatic human immunodeficiency virus (HIV) infection. Design: Randomized, placebo-controlled, and double-blind study. Setting: Outpatient clinic of a government referral-based research hospital. Patients: Volunteer sample of 34 patients with asymptomatic HIV infection who had CD4 counts of 400 cells/mm3 or more, positive peripheral blood mononuclear cell cultures for HIV, or p24 antigenemia. Interventions: Patients were randomly assigned to receive either IFN-α or placebo, 35 x 106 units per day subcutaneously. Doses of IFN-α or placebo were modified according to predefined laboratory and clinical criteria. Therapy lasted at least 12 weeks. Measurements and Main Results: Seventeen patients were randomly assigned to each group. The two groups had similar mean CD4 counts at study entry. Thirty-five percent of patients assigned to receive IFN-α withdrew from the study because of toxicity. The average daily dose of IFN-α was 17.5 x 106 units. All patients receiving IFN-α reported flu-like symptoms; other toxicities included granulocytopenia (55%) and elevated liver enzyme levels (45%). While receiving IFN-α, 7 patients (41%) became HIV culture negative (three or more consecutive negative peripheral blood mononuclear cell cultures taken at least 2 weeks apart). In contrast, 2 patients in the placebo group (13%) became culture negative while on study (P = 0.05). During the treatment period, CD4 lymphocyte percentages were sustained at or above the baseline level in patients receiving IFN-α and declined slightly in patients receiving placebo. Of the 32 study patients followed after study (range, 5 to 33 months), no patients in the IFN-α group developed an acquired immunodeficiency syndrome (AIDS)-defining opportunistic infection, compared with 5 patients in the placebo group (P = 0.02). Conclusions: Treatment of early-stage HIV infection with IFN-α can result in a decrease in frequency of viral isolation. Although its use may be accompanied by dose-dependent toxicities, IFN-α may have a role in slowing progression of HIV disease." @default.
• W2116696460 created "2016-06-24" @default.
• W2116696460 creator A5005816722 @default.
• W2116696460 creator A5009813178 @default.
• W2116696460 creator A5017141290 @default.
• W2116696460 creator A5018536389 @default.
• W2116696460 creator A5021779794 @default.
• W2116696460 creator A5023499969 @default.
• W2116696460 creator A5026161080 @default.
• W2116696460 creator A5031736334 @default.
• W2116696460 creator A5039634321 @default.
• W2116696460 creator A5040948574 @default.
• W2116696460 creator A5041754237 @default.
• W2116696460 creator A5043417594 @default.
• W2116696460 creator A5044817385 @default.
• W2116696460 creator A5056349739 @default.
• W2116696460 creator A5068358102 @default.
• W2116696460 date "1990-06-01" @default.
• W2116696460 modified "2023-09-27" @default.
• W2116696460 title "Interferon-α in Patients with Asymptomatic Human Immunodeficiency Virus (HIV) Infection" @default.
• W2116696460 cites W197994193 @default.
• W2116696460 cites W2053905319 @default.
• W2116696460 cites W2066957976 @default.
• W2116696460 cites W2076610816 @default.
• W2116696460 cites W2086186867 @default.
• W2116696460 cites W2088255505 @default.
• W2116696460 cites W2129816627 @default.
• W2116696460 cites W2130594297 @default.
• W2116696460 cites W2132871317 @default.
• W2116696460 cites W2137222688 @default.
• W2116696460 cites W2214929347 @default.
• W2116696460 cites W2254611195 @default.
• W2116696460 cites W2333399282 @default.
• W2116696460 cites W2418847381 @default.
• W2116696460 cites W2431213041 @default.
• W2116696460 cites W2613310160 @default.
• W2116696460 doi "https://doi.org/10.7326/0003-4819-112-11-805" @default.
• W2116696460 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/1971503" @default.
• W2116696460 hasPublicationYear "1990" @default.
• W2116696460 type Work @default.
• W2116696460 sameAs 2116696460 @default.
• W2116696460 citedByCount "213" @default.
• W2116696460 countsByYear W21166964602012 @default.
• W2116696460 countsByYear W21166964602013 @default.
• W2116696460 countsByYear W21166964602014 @default.
• W2116696460 countsByYear W21166964602015 @default.
• W2116696460 countsByYear W21166964602016 @default.
• W2116696460 countsByYear W21166964602017 @default.
• W2116696460 countsByYear W21166964602018 @default.
• W2116696460 countsByYear W21166964602019 @default.
• W2116696460 countsByYear W21166964602020 @default.
• W2116696460 countsByYear W21166964602021 @default.
• W2116696460 countsByYear W21166964602022 @default.
• W2116696460 countsByYear W21166964602023 @default.
• W2116696460 crossrefType "journal-article" @default.
• W2116696460 hasAuthorship W2116696460A5005816722 @default.
• W2116696460 hasAuthorship W2116696460A5009813178 @default.
• W2116696460 hasAuthorship W2116696460A5017141290 @default.
• W2116696460 hasAuthorship W2116696460A5018536389 @default.
• W2116696460 hasAuthorship W2116696460A5021779794 @default.
• W2116696460 hasAuthorship W2116696460A5023499969 @default.
• W2116696460 hasAuthorship W2116696460A5026161080 @default.
• W2116696460 hasAuthorship W2116696460A5031736334 @default.
• W2116696460 hasAuthorship W2116696460A5039634321 @default.
• W2116696460 hasAuthorship W2116696460A5040948574 @default.
• W2116696460 hasAuthorship W2116696460A5041754237 @default.
• W2116696460 hasAuthorship W2116696460A5043417594 @default.
• W2116696460 hasAuthorship W2116696460A5044817385 @default.
• W2116696460 hasAuthorship W2116696460A5056349739 @default.
• W2116696460 hasAuthorship W2116696460A5068358102 @default.
• W2116696460 hasConcept C126322002 @default.
• W2116696460 hasConcept C142462285 @default.
• W2116696460 hasConcept C142724271 @default.
• W2116696460 hasConcept C168563851 @default.
• W2116696460 hasConcept C203014093 @default.
• W2116696460 hasConcept C204787440 @default.
• W2116696460 hasConcept C27081682 @default.
• W2116696460 hasConcept C2776768635 @default.
• W2116696460 hasConcept C2777761686 @default.
• W2116696460 hasConcept C2777910003 @default.
• W2116696460 hasConcept C2779298103 @default.
• W2116696460 hasConcept C2993143319 @default.
• W2116696460 hasConcept C3013748606 @default.
• W2116696460 hasConcept C3020110884 @default.
• W2116696460 hasConcept C535046627 @default.
• W2116696460 hasConcept C6557445 @default.
• W2116696460 hasConcept C71924100 @default.
• W2116696460 hasConcept C86803240 @default.
• W2116696460 hasConcept C90924648 @default.
• W2116696460 hasConceptScore W2116696460C126322002 @default.
• W2116696460 hasConceptScore W2116696460C142462285 @default.
• W2116696460 hasConceptScore W2116696460C142724271 @default.
• W2116696460 hasConceptScore W2116696460C168563851 @default.
• W2116696460 hasConceptScore W2116696460C203014093 @default.
• W2116696460 hasConceptScore W2116696460C204787440 @default.
• W2116696460 hasConceptScore W2116696460C27081682 @default.
• W2116696460 hasConceptScore W2116696460C2776768635 @default.
• W2116696460 hasConceptScore W2116696460C2777761686 @default.

• next